137 related articles for article (PubMed ID: 7537608)
21. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis.
Zeller W; Gutensohn K; Stockschläder M; Dierlamm J; Kröger N; Koehne G; Hummel K; Kabisch H; Weh HJ; Kühnl P; Hossfeld DK; Zander AR
Bone Marrow Transplant; 1996 May; 17(5):709-13. PubMed ID: 8733686
[TBL] [Abstract][Full Text] [Related]
22. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor.
Schwartzberg LS; Birch R; Hazelton B; Tauer KW; Lee P; Altemose R; George C; Blanco R; Wittlin F; Cohen J
J Hematother; 1992; 1(4):317-27. PubMed ID: 1285381
[TBL] [Abstract][Full Text] [Related]
23. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
[TBL] [Abstract][Full Text] [Related]
24. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma.
Kim S; Kim HJ; Park JS; Lee J; Chi HS; Park CJ; Huh J; Suh C
Ann Hematol; 2005 Oct; 84(11):742-7. PubMed ID: 16132903
[TBL] [Abstract][Full Text] [Related]
25. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
[TBL] [Abstract][Full Text] [Related]
26. Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens.
Bender JG; Lum L; Unverzagt KL; Lee W; Van Epps D; George S; Coon J; Ghalie R; McLeod B; Kaizer H
Bone Marrow Transplant; 1994 Apr; 13(4):479-85. PubMed ID: 7517260
[TBL] [Abstract][Full Text] [Related]
27. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.
Gazitt Y; Callander N; Freytes CO; Shaughnessy P; Liu Q; Tsai TW; Devore P
J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498
[TBL] [Abstract][Full Text] [Related]
28. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis.
Möhle R; Pförsich M; Fruehauf S; Witt B; Krämer A; Haas R
Bone Marrow Transplant; 1994 Nov; 14(5):827-32. PubMed ID: 7534163
[TBL] [Abstract][Full Text] [Related]
29. Combined chemotherapy and granulocyte colony-stimulating factor (G-CSF) mobilise large numbers of peripheral blood progenitor cells in pretreated patients.
Lickliter JD; Begley CG; Boyd AW; Szer J; Grigg AP
Leuk Lymphoma; 1994 Sep; 15(1-2):91-7. PubMed ID: 7532059
[TBL] [Abstract][Full Text] [Related]
30. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
[TBL] [Abstract][Full Text] [Related]
31. Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma.
Zimmerman TM; Michelson GC; Mick R; Grinblatt DL; Williams SF
J Clin Apher; 1999; 14(1):31-4. PubMed ID: 10355661
[TBL] [Abstract][Full Text] [Related]
32. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
McQuaker I; Haynes A; Stainer C; Byrne J; Russell N
Bone Marrow Transplant; 1999 Oct; 24(7):715-22. PubMed ID: 10516673
[TBL] [Abstract][Full Text] [Related]
33. In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression.
Villaron EM; Almeida J; Lopez-Holgado N; Sanchez-Guijo FM; Alberca M; Blanco B; Sanchez-Abarca LI; Lopez O; Perez-Simon JA; San Miguel JF; del Cañizo MC
Transfus Apher Sci; 2007 Oct; 37(2):145-56. PubMed ID: 17983836
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies.
Sheridan WP; Begley CG; To LB; Grigg A; Szer J; Maher D; Green MD; Rowlings PA; McGrath KM; Cebon J
Bone Marrow Transplant; 1994 Jul; 14(1):105-11. PubMed ID: 7524904
[TBL] [Abstract][Full Text] [Related]
35. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
[TBL] [Abstract][Full Text] [Related]
36. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
[TBL] [Abstract][Full Text] [Related]
37. Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients.
Petit J; Boqué C; Cancelas JA; Sarrà J; Muñoz J; Garcia J; Grañena A
Leuk Lymphoma; 1999 Jun; 34(1-2):119-27. PubMed ID: 10350339
[TBL] [Abstract][Full Text] [Related]
38. Plastic-adherent progenitor cells in mobilized peripheral blood progenitor cell collections.
Scott MA; Apperley JF; Jestice HK; Bloxham DM; Marcus RE; Gordon MY
Blood; 1995 Dec; 86(12):4468-73. PubMed ID: 8541535
[TBL] [Abstract][Full Text] [Related]
39. Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF.
Ricca I; Compagno M; Ladetto M; Rocci A; Dell'Aquila M; Omedè P; De Marco F; D'Antico S; Caracciolo D; Ferrero D; Carlo-Stella C; Tarella C
Leukemia; 2005 Apr; 19(4):644-51. PubMed ID: 15716989
[TBL] [Abstract][Full Text] [Related]
40. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma.
Goldschmidt H; Hegenbart U; Haas R; Hunstein W
Bone Marrow Transplant; 1996 May; 17(5):691-7. PubMed ID: 8733683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
